Simultaneously, studies have shown that patients with DN have higher HIF-1α levels and sodium-dependent glucose transporters 2 inhibitors, recently used to treat DN, also target HIF-1α [12]. This evidence concerns the gene HIF1A and liver dysplastic nodule.